Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040918 · ClinicalTrials.gov registry record · Phase 1
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06040918 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 10 participants.
The verdict
NCT06040918, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors undergoing a procedure called apheresis.
Interventions
- DRUG N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2024-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06040918
The ClinicalTrials.gov registry entry for NCT06040918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-803 is the first listed.
NCT06040918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06040918 about?
NCT06040918 is a clinical study titled "Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis". This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors undergoing a procedure called apheresis.
What is the current status of trial NCT06040918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-10-04. Estimated completion is 2024-09-03.
What interventions are being tested in trial NCT06040918?
The interventions under investigation include: N-803 (DRUG).
Who is sponsoring clinical trial NCT06040918?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.